Picture of Cerevel Therapeutics Holdings logo

CERE Cerevel Therapeutics Holdings Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapMomentum Trap

Annual income statement for Cerevel Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Total Revenue00000
Cost of Revenue
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses149220368447
Operating Profit0-149-220-368-447
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-152-225-351-432
Provision for Income Taxes
Net Income After Taxes-152-225-352-433
Net Income Before Extraordinary Items
Net Income-152-225-352-433
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income0-148-225-352-433
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-2.01-1.65-2.32-2.67